Folitixorin

Summary

Folitixorin (CHEMBL117348) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 457.4 Da · C20H23N7O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL117348
Name	Folitixorin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	135400185
ChEBI	CHEBI:20502
Molecular formula	C20H23N7O6
Molecular weight	457.4
InChIKey	QYNUQALWYRSVHF-ABLWVSNPSA-N

SMILES: C1C2CN(CN2C3=C(N1)N=C(NC3=O)N)C4=CC=C(C=C4)C(=O)N[C@@H](CCC(=O)O)C(=O)O

IUPAC name: (2S)-2-[[4-(3-amino-1-oxo-2,5,6,6a,7,9-hexahydroimidazo[1,5-f]pteridin-8-yl)benzoyl]amino]pentanedioic acid

Also known as: Folitixorin, Folitixorina, Folitixorine, FOLITIXORIN

Parent form; salt/anhydrous children: CHEMBL2103811

Patent coverage: 328 distinct patent families (567 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 518 (91%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).